Weight: __________ kg   Height: __________ cm

Allergies: ___________________________________________________________

Diagnosis Code: _____________________________________________________

Treatment Start Date: ___________   Patient to follow up with provider on date: _____________

**This plan will expire after 365 days at which time a new order will need to be placed**

GUIDELINES FOR ORDERING
1. Send FACE SHEET and H&P or most recent chart note.
2. Indicated for use in patients with Fabry disease. Reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types
3. Please encourage patients to enroll in the Fabry registry by visiting www.fabryregistry.com or calling 1-800-745-4447.
4. Patients with advanced Fabry disease may have compromised cardiac function which may predispose them to a higher risk of severe complications from infusion reactions.

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)
Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)

- acetaminophen (TYLENOL) tablet, oral, ONCE, every visit
  - 325 mg
  - 500 mg
  - 650 mg
  - 1000 mg
- diphenhydRAMINE (BENADRYL) capsule, oral, ONCE, every visit
  - 25 mg
  - 50 mg
- loratadine (CLARITIN) tablet, oral, ONCE, every visit
  (Choose as alternative to diphenhydRAMINE if needed)
    - 5 mg
    - 10 mg

MEDICATIONS:
Agalsidase beta (FABRAZYME) 1 mg/kg = _______ mg in NaCl 0.9% IV ONCE, every 2 weeks x _______ doses (Pharmacist will round dose to nearest 5 mg vial and modify during order verification)

Administer using an in-line low protein binding 0.2 micron filter. Initial infusion: Rate should not exceed 15 mg/hr. Subsequent infusions if no infusion reactions: rate may be increased in increments of 3 to 5 mg/hr to allow a total infusion time of no less than 1.5 hours. Total volume will be between 50-500 mL based on calculated dose:

<table>
<thead>
<tr>
<th>Calculated Dose</th>
<th>Minimum Total Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 35 mg</td>
<td>50 mL</td>
</tr>
<tr>
<td>35.1 – 70 mg</td>
<td>100 mL</td>
</tr>
<tr>
<td>70.1 – 100 mg</td>
<td>250 mL</td>
</tr>
<tr>
<td>&gt; 100 mg</td>
<td>500 mL</td>
</tr>
</tbody>
</table>
NURSING ORDERS:
1. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
2. VITAL SIGNS – Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to infusion, with every rate increase, then hourly until infusion is complete.
3. Observe patient for 60 minutes following infusion (unless prescriber indicates this is not necessary).
4. Reschedule patient for next weekly infusion.

HYPERSENSITIVITY MEDICATIONS:
1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydramine (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 doses for hypersensitivity reaction
3. epinephrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity reaction

By signing below, I represent the following:
I am responsible for the care of the patient (who is identified at the top of this form);
I hold an active, unrestricted license to practice medicine in: □ Oregon □ _______________________(check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);

My physician license number is # ______________________ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order infusion of the medication described above for the patient identified on this form.

Provider signature: ____________________________ Date/Time: __________________________
Printed Name: ____________________________ Phone: ______________ Fax: ______________
OLC Central Intake Nurse:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient’s preferred clinic location:

☐ Beaverton
  OHSU Knight Cancer Institute
  15700 SW Greystone Court
  Beaverton, OR 97006
  Phone number: 971-262-9000
  Fax number: 503-346-8058

☐ NW Portland
  Legacy Good Samaritan campus
  Medical Office Building 3, Suite 150
  1130 NW 22nd Ave.
  Portland, OR 97210
  Phone number: 971-262-9600
  Fax number: 503-346-8058

☐ Gresham
  Legacy Mount Hood campus
  Medical Office Building 3, Suite 140
  24988 SE Stark
  Gresham, OR 97030
  Phone number: 971-262-9500
  Fax number: 503-346-8058

☐ Tualatin
  Legacy Meridian Park campus
  Medical Office Building 2, Suite 140
  19260 SW 65th Ave.
  Tualatin, OR 97062
  Phone number: 971-262-9700
  Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders